- Home
- LBGJ vs ZBIO Comparison
LBGJ vs ZBIO Comparison
Compare LBGJ & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- ZBIO
- Stock Information
- Founded
- LBGJ 2007
- ZBIO 2019
- Country
- LBGJ China
- ZBIO United States
- Employees
- LBGJ N/A
- ZBIO N/A
- Industry
- LBGJ
- ZBIO
- Sector
- LBGJ
- ZBIO
- Exchange
- LBGJ NYSE
- ZBIO NYSE
- Market Cap
- LBGJ 24.7M
- ZBIO 389.2M
- IPO Year
- LBGJ 2024
- ZBIO 2024
- Fundamental
- Price
- LBGJ $1.19
- ZBIO $10.41
- Analyst Decision
- LBGJ
- ZBIO Strong Buy
- Analyst Count
- LBGJ 0
- ZBIO 7
- Target Price
- LBGJ N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- LBGJ 12.8K
- ZBIO 221.4K
- Earning Date
- LBGJ 08-15-2025
- ZBIO 08-16-2025
- Dividend Yield
- LBGJ N/A
- ZBIO N/A
- EPS Growth
- LBGJ N/A
- ZBIO N/A
- EPS
- LBGJ N/A
- ZBIO N/A
- Revenue
- LBGJ $11,781,015.00
- ZBIO $15,000,000.00
- Revenue This Year
- LBGJ N/A
- ZBIO $206.00
- Revenue Next Year
- LBGJ N/A
- ZBIO $41.92
- P/E Ratio
- LBGJ N/A
- ZBIO N/A
- Revenue Growth
- LBGJ 21.82
- ZBIO N/A
- 52 Week Low
- LBGJ $1.02
- ZBIO $5.83
- 52 Week High
- LBGJ $5.50
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- ZBIO N/A
- Support Level
- LBGJ N/A
- ZBIO N/A
- Resistance Level
- LBGJ N/A
- ZBIO N/A
- Average True Range (ATR)
- LBGJ 0.00
- ZBIO 0.00
- MACD
- LBGJ 0.00
- ZBIO 0.00
- Stochastic Oscillator
- LBGJ 0.00
- ZBIO 0.00
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.